AML, MDS
Conditions
Keywords
HA-2, TSC-101, AML, MDS, Adoptive Cell Therapy, T-cell receptor, T lymphocyte, TCR-engineered T cells, bone marrow transplant, haploidentical, allogenic stem cell transplant, BMT, RIC, ALLOHA-2, Mismatched unrelated donors MMUD, HCT, Hematopoietic cell transplantation
Brief summary
This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study will compare TSC-101 plus standard of care (SOC) versus SOC alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors.
Detailed description
This is a multicenter, genetically-randomized, controlled, Phase 3 study designed to evaluate the efficacy and safety of TSC-101 in adult participants with AML or MDS undergoing allogeneic peripheral blood stem cell transplantation following reduced-intensity conditioning (RIC). TSC-101 is a donor-derived, genetically engineered T-cell therapy designed to express a therapeutic T-cell receptor recognizing the HA-2 minor histocompatibility antigen presented by HLA-A\*02:01. The study is intended to evaluate whether administration of TSC-101 following transplantation can improve clinical outcomes compared with standard transplantation alone. Eligible participants are adults with AML or MDS who are candidates for first allogeneic HCT using a haploidentical or mismatched unrelated donor and post-transplant. Participants assigned to the treatment arm must be HLA-A\*02:01 positive, express HA-2, and have a study-eligible HLA-A\*02-negative donor. Participants who are HLA-A\*02:01 positive but do not have a study-eligible donor, as well as participants who are HLA-A\*02:01 negative, may be assigned to the control arm. Approximately 310 participants will be enrolled, with approximately 155 participants in each study arm. Participants assigned to the treatment arm will receive two infusions of TSC-101 following recovery after transplantation. The first infusion is planned approximately 21 days after HCT (Day +14 to Day +35), and the second infusion is planned approximately 40 days after the first infusion (40 to 68 days after Infusion 1). All participants will receive SOC transplantation procedures, including one of several protocol-specified RIC regimens followed by peripheral blood stem cell transplantation and post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GvHD) prophylaxis. Safety will be monitored through ongoing review of adverse events, laboratory assessments, and clinical evaluations. An independent Data Safety Monitoring Board (DSMB) will periodically review safety data and study conduct and make recommendations regarding continuation, modification, or termination of the study. This is an event-driven study. Participants will be followed for up to 3 years after HCT. Participants who receive at least one TSC-101 infusion will subsequently participate in a separate long-term follow-up study for up to 15 years following their final TSC-101 infusion to monitor long-term safety and survival outcomes.
Interventions
DRUGTSC-101
SOC + TSC-101
OTHERControl
SOC alone
Sponsors
TScan Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase 3 genetically-randomized, controlled study designed to evaluate the efficacy of TSC-101 following RIC HCT vs. RIC HCT as standard of care (SOC).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subject Inclusion Criteria: 1. Patient aged ≥ 18 years at the time of signing informed consent. 2. Karnofsky Performance Status (KPS) ≥50 at the time of the screening visit. 3. Undergoing first allo-HCT with a diagnosis of: * AML with bone marrow blasts \< 5%, absence of circulating blasts, and absence of extramedullary disease. * MDS 4. Must express HLA-A\*02:01 as determined by pre-transplant institutional SOC work-up to be eligible for the treatment arm. 5. Must have the HA-2 positive genotype to be eligible for the treatment arm. 6. Undergoing RIC HCT using a haplo donor or MMUD. * Donors for treatment-arm subjects must be HLA-A\*02-negative. * Donors for control-arm subjects do not have to be HLA-A\*02-negative. 7. Undergoing use of PTCy for GvHD prophylaxis at standard doses. 8. Use of peripheral blood stem cell source. 9. Organ function parameters for transplant eligibility are met per institutional standards. Where organ function may fall outside of institutional standard for transplant, and patient is still proceeding to transplant, the case should be reviewed and approved by the MedicalMonitor. 10. Patient or legally authorized representative (LAR) capable of giving signed informed consent and willingness to comply with the requirements and restrictions listed in the informed consent form (ICF) and clinical protocol. 11. Agrees to participate in long-term follow-up (LTFU) for up to 15 years post the final infusion of TSC-101 if they receive a TSC-101 infusion. 12. Contraceptive use by male and female subjects must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. At a minimum: * A male subject must agree to use a highly effective contraceptive during the intervention period and for at least 12 months after the last TSC-101 infusion and refrain from donating sperm during this period. * A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: * Not a woman of childbearing potential (WOCBP) as defined in Appendix 2 OR * A WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during the intervention period and for at least 12 months after the last TSC-101 infusion. Subject
Exclusion criteria
Patients are excluded from the study if any of the following criteria apply: 1. Potential treatment-arm patient is positive for HLA-A\*02:07. • Patients considered for the control arm can be positive for HLA-A\*02 (including HLA-A\*02:07). 2. For patients with AML: those in third complete remission (CR3) or greater, partial remission, or with active AML disease. 3. If patient required hemodialysis or mechanical ventilation within 3 months prior to enrollment, circumstances must be discussed with the Sponsor Medical Monitor. 4. Prior allo-HCT. 5. Use of anti-thymocyte globulin (ATG), alemtuzumab, or other in vivo or ex vivo T-cell depleting agents from Day -14 (pre-HCT) through end of study (EOS). Corticosteroids and maintenance therapies may be allowed under certain circumstances. 6. History of hypersensitivity to murine proteins. 7. Enrollment in a concomitant study with an investigational agent. All other concomitant trials must be reviewed and approved by the Medical Monitor. 8. Cardiac disease, defined as: * Uncontrolled or symptomatic angina within the past 3 months. * History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes). Atrial fibrillation with controlled ventricular response on treatment is not an exclusion. * Myocardial infarction \< 6 months from study entry. * Uncontrolled or symptomatic congestive heart failure. * Cardiac ejection fraction at rest of less than 40% or shortening fraction of less than 22% by echocardiogram or radionuclide scan (multi-gated acquisition \[MUGA\] scan). 9. Medical or psychological conditions that would make the patient an unsuitable candidate for participation on a cell therapy trial, including active central nervous system disease and/or prior malignancy(s) within the last 3 years, except: * Lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ will be allowed. Cancer treated with curative intent ≥ 3 years previously will be allowed Donor Inclusion Criteria: 1. Male or female ≥ 50 kg and aged ≥ 16 years at the time of signing informed consent who meet the criteria to donate as per the institutional SOC. 2. Capable of giving signed informed consent, or assent/parental consent per institutional SOC, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. 3. For treatment-arm donors: able to undergo peripheral blood stem cell (PBSC) collection and at least 2 rounds of leukapheresis (for both TSC-101 manufacturing and the stem cell collection for HCT). 4. For treatment-arm donors: negative for all HLA-A\*02 alleles • Donors for control-arm subjects do not have to be negative for HLA-A\*02 alleles. Donor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relapse-free survival (RFS) | 3 years | To determine the efficacy of TSC-101 by assessing relapse-free survival (RFS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival (EFS) | 3 years | To determine the efficacy of TSC-101 by event-free survival (EFS) |
| Overall survival (OS) | 3 years | To determine the efficacy of TSC-101 by overall survival (OS) |
| Time to relapse (TTR) | 3 years | To determine the efficacy of TSC-101 by assessing time to relapse (TTR) |
| Changes over time in Quality of Life Score - EQ-5D-5L | 3 years | To determine the efficacy of TSC-101 by tracking changes over time in quality of life scores of EQ-5D-5L |
| Changes over time in Quality of Life Score - FACT-Leu | 3 years | To determine the efficacy of TSC-101 by tracking changes over time in quality of life scores of FACT-Leu |
| Changes over Quality of Life Scores in FACT-BMT | 3 years | To determine the efficacy of TSC-101 by tracking changes over time in quality of life scores of FACT-BMT |
Countries
United States
Contacts
CONTACTMarlyane Motta
STUDY_DIRECTORShrikanta Chattopadhyay, MD
TScan Therapeutics
Outcome results
None listed